On 28 April 2026, Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) disclosed that its board of directors has resolved to seek shareholder approval for a Restricted Share Unit (RSU) Incentive Scheme covering the company’s H shares.

The proposed RSU plan aims to strengthen Boan Biotech’s long-term talent incentives, motivate core employees, and better align the interests of shareholders, management and the company, thereby supporting sustainable growth.

Key features of the proposal include: • Funding source: The RSU scheme will be supported by existing shares; no new share issuance is involved. • Regulatory framework: Classified as a share scheme funded by existing shares under Chapter 17 of the Hong Kong Listing Rules and falls under the disclosure requirements of Rule 17.12. • Approval process: Although shareholder approval is not required under the Listing Rules, Boan Biotech’s articles of association mandate that the RSU scheme and related authorisations receive shareholder consent via special resolutions at an upcoming general meeting. • Implementation authority: Subject to shareholder approval, the board and/or its authorised delegates will be empowered to handle all matters related to the scheme.

A circular detailing the RSU plan and the notice of the general meeting will be published on the HKEX and company websites in due course.

Chairlady, Chief Executive Officer and Executive Director Jiang Hua signed the announcement in Yantai, PRC. As of the announcement date, Boan Biotech’s board comprises two executive directors (Jiang Hua, Wang Shenghan), three non-executive directors (Liu Yuanchong, Li Li, Li Shixu) and three independent non-executive directors (Professor Shi Luwen, Dai Jixiong, Dr. Yu Jialin).